In Vivo Parasitological Measures of Artemisinin Susceptibility
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Parasite clearance data from 18,699 patients with falciparum malaria treated with an artemisinin derivative in areas of low (n=14,539), moderate (n=2077), and high (n=2083) levels of malaria transmission across the world were analyzed to determine the factors that affect clearance rates and identify a simple in vivo screening measure for artemisinin resistance. The main factor affecting parasite clearance time was parasite density on admission. Clearance rates were faster in high-transmission settings and with more effective partner drugs in artemisinin-based combination treatments (ACTs). The result of the malaria blood smear on day 3 (72 h) was a good predictor of subsequent treatment failure and provides a simple screening measure for artemisinin resistance. Artemisinin resistance is highly unlikely if the proportion of patients with parasite densities of <100,000 parasites/microL given the currently recommended 3-day ACT who have a positive smear result on day 3 is <3%; that is, for n patients the observed number with a positive smear result on day 3 does not exceed (n + 60)/24.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424 · cited 1×
“therefore associated with an increase in this proportion [14].”
BackgroundSelf-citationQinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954 · cited 2×
“falciparum malaria has developed there [2, 13].”
BackgroundSelf-citationNosten, F., van Vugt, M., Price, R., Luxemburger, C., Thway, K., Brockman, A., McGready, R., ter Kuile, F., Looareesuwan, S., & White, N. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02505-8 · Cited by 500
Self-citation
Cited by
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
Self-citationDondorp, A. M., Fanello, C. I., Hendriksen, I. C., Gomes, E., Seni, A., Chhaganlal, K. D., Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61924-1 · Cited by 1,022
Self-citationEmergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., McGready, R., ler Moo, C., Al-Saai, S., Dondorp, A. M., Lwin, K. M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60484-x · Cited by 924
Self-citationAmaratunga, C., Lim, P., Suon, S., Sreng, S., Mao, S., Sopha, C., Sam, B., Dek, D., Try, V., Amato, R., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00487-9 · Cited by 493
WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group (2015) · BMC Medicine · doi:10.1186/s12916-015-0456-7 · Cited by 464
Uwimana, A., Umulisa, N., Venkatesan, M., Svigel, S. S., Zhou, Z., Munyaneza, T., Habimana, R. M., Rucogoza, A., Moriarty, L. F., Sandford, R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00142-0 · Cited by 435
WWARN K13 Genotype-Phenotype Study Group (2019) · BMC Medicine · doi:10.1186/s12916-018-1207-3 · Cited by 320
Flegg, J. A., Guerin, P. J., White, N. J., & Stepniewska, K. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-339 · Cited by 285
Self-citationMalaria in the Greater Mekong Subregion: heterogeneity and complexity.
Cui, L., Yan, G., Sattabongkot, J., Cao, Y., Chen, B., Chen, X., Fan, Q., Fang, Q., Jongwutiwes, S., Parker, D., et al. (2012) · Acta Tropica · doi:10.1016/j.actatropica.2011.02.016 · Cited by 277
“Historically, artemisinin monotherapy has been associated with a baseline recrudescence rate of 3-5% (Li et al., 1994; Stepniewska et al., 2010); however, this rate has been increased to almost 30% in some regions (WHO, 2010a).”
BackgroundWhite, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230
“The magnitude of the effect of immunity on parasite clearance can be assessed by comparing parasite clearance rates in drug sensitive infections with similar drug exposure between high transmission and low transmission areas [32, 100], by assessing the effect of age on parasite clearance within an area of moderate or…”
BackgroundSelf-citationDrug-Resistant Malaria: The Era of ACT
Lin, J. T., Juliano, J. J., & Wongsrichanalai, C. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0099-y · Cited by 121
Talisuna, A. O. (2014) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000217 · Cited by 10
Metadata
- Authors
- Stepniewska, K., Ashley, E., Lee, S. J., Anstey, N., Barnes, K. I., Binh, T. Q., D’Alessandro, U., Day, N. P. J., de Vries, P. J., Dorsey, G., Guthmann, J., Mayxay, M., Newton, P. N., Olliaro, P., Osorio, L., Price, R. N., Rowland, M., Smithuis, F., Taylor, W. R. J., Nosten, F., & White, N. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-15
- Volume
- 201
- Issue
- 4
- Pages
- 570-579
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W1992148637
- Cited by
- 155
- References
- 3
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.